Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated ...

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...

With the recent approval of apixaban for stroke prevention in AF, all 3 of the new oral anticoagulants are now available, leaving doctors with the dilemma of which one to use in which patients.

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...

A 2012 study using indirect comparisons indicated that apixaban had a lower risk of major hemorrhage compared with other DOACs. And a 2018 analysis based on claims data showed that apixaban carried ...

Gastrointestinal (GI) bleeds are about 20%–28% less likely in patients with atrial fibrillation (AF) taking apixaban (Eliquis) compared with other direct oral anticoagulants (DOACs), an ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure. Bleeding risk does not appear to increase when apixaban is given concomitantly with cardiac P ...

In the overall trial, apixaban was not superior to standard care for the prevention of clinical events, irrespective of the need for oral anticoagulation. In the substudy, investigators evaluated the ...